Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025857581> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2025857581 endingPage "334" @default.
- W2025857581 startingPage "327" @default.
- W2025857581 abstract "Triamterene (TA), a potassium-sparing diuretic, is extensively metabolized by hydroxylation in 4'-position and subsequent conjugation by cytosolic sulfotransferases. To identify the cytochrome P450 enzyme(s) catalyzing hydroxylation of triamterene (the rate-limiting step in the formation of the sulfate ester (STA)), in vitro incubation studies were performed with human liver microsomes.Initial rates of TA hydroxylation (0 - 300 microM) were determined during a ten-minute-incubation period with liver microsomes of two donors. The role of individual CYP enzymes was determined by pre-incubation with selective inhibitors/alternative substrates. Vice versa, the effect of TA (0 - 500 microM) on 3-demethylation of caffeine (0 - 1,000 microM) was assessed. Metabolite concentrations were estimated by reversed-phase HPLC methods.TA Km values without inhibitors were 60 and 142 microM, Vmax was 177 and 220 pmol/min/mg protein, respectively. Mean inhibitor induced changes of 4'-hydroxy-TA formation were as follows: Furafylline 25 microM (CYP1A2), complete inhibition (-100%); omeprazole 250 microM (CYP1A2 inhibitor/CYP2C 19 substrate), -30%; coumarin 25 microM (CYP2A6), -11%; quinidine 25 microM (CYP2D6), -9%; ketoconazole 25 microM (CYP3A), -18%; and erythromycin 250 microM (CYP3A), -8%. In the reverse inhibition studies, TA competitively inhibited caffeine 3-demethylation with Ki values of 65 and 111 microM, respectively.4'-hydroxylation of TA in humans appears to be mediated exclusively by CYP1A2. Inhibition or induction of CYP1A2 will change the time course of both TA and its active phase-II metabolite. The net pharmacodynamic effect of such changes is difficult to predict and needs to be evaluated in clinical studies." @default.
- W2025857581 created "2016-06-24" @default.
- W2025857581 creator A5008365289 @default.
- W2025857581 creator A5031177740 @default.
- W2025857581 creator A5051448005 @default.
- W2025857581 creator A5058859139 @default.
- W2025857581 creator A5061101002 @default.
- W2025857581 date "2005-07-01" @default.
- W2025857581 modified "2023-10-10" @default.
- W2025857581 title "Rate-limiting biotransformation of triamterene is mediated by CYP1A2" @default.
- W2025857581 doi "https://doi.org/10.5414/cpp43327" @default.
- W2025857581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16035375" @default.
- W2025857581 hasPublicationYear "2005" @default.
- W2025857581 type Work @default.
- W2025857581 sameAs 2025857581 @default.
- W2025857581 citedByCount "16" @default.
- W2025857581 countsByYear W20258575812012 @default.
- W2025857581 countsByYear W20258575812014 @default.
- W2025857581 countsByYear W20258575812016 @default.
- W2025857581 countsByYear W20258575812017 @default.
- W2025857581 countsByYear W20258575812018 @default.
- W2025857581 countsByYear W20258575812019 @default.
- W2025857581 countsByYear W20258575812021 @default.
- W2025857581 countsByYear W20258575812022 @default.
- W2025857581 crossrefType "journal-article" @default.
- W2025857581 hasAuthorship W2025857581A5008365289 @default.
- W2025857581 hasAuthorship W2025857581A5031177740 @default.
- W2025857581 hasAuthorship W2025857581A5051448005 @default.
- W2025857581 hasAuthorship W2025857581A5058859139 @default.
- W2025857581 hasAuthorship W2025857581A5061101002 @default.
- W2025857581 hasConcept C104317684 @default.
- W2025857581 hasConcept C134018914 @default.
- W2025857581 hasConcept C150194340 @default.
- W2025857581 hasConcept C181199279 @default.
- W2025857581 hasConcept C185592680 @default.
- W2025857581 hasConcept C190727270 @default.
- W2025857581 hasConcept C202199734 @default.
- W2025857581 hasConcept C2777477808 @default.
- W2025857581 hasConcept C2778500429 @default.
- W2025857581 hasConcept C2781109383 @default.
- W2025857581 hasConcept C55493867 @default.
- W2025857581 hasConcept C86745063 @default.
- W2025857581 hasConcept C86803240 @default.
- W2025857581 hasConcept C87644729 @default.
- W2025857581 hasConcept C98274493 @default.
- W2025857581 hasConceptScore W2025857581C104317684 @default.
- W2025857581 hasConceptScore W2025857581C134018914 @default.
- W2025857581 hasConceptScore W2025857581C150194340 @default.
- W2025857581 hasConceptScore W2025857581C181199279 @default.
- W2025857581 hasConceptScore W2025857581C185592680 @default.
- W2025857581 hasConceptScore W2025857581C190727270 @default.
- W2025857581 hasConceptScore W2025857581C202199734 @default.
- W2025857581 hasConceptScore W2025857581C2777477808 @default.
- W2025857581 hasConceptScore W2025857581C2778500429 @default.
- W2025857581 hasConceptScore W2025857581C2781109383 @default.
- W2025857581 hasConceptScore W2025857581C55493867 @default.
- W2025857581 hasConceptScore W2025857581C86745063 @default.
- W2025857581 hasConceptScore W2025857581C86803240 @default.
- W2025857581 hasConceptScore W2025857581C87644729 @default.
- W2025857581 hasConceptScore W2025857581C98274493 @default.
- W2025857581 hasIssue "07" @default.
- W2025857581 hasLocation W20258575811 @default.
- W2025857581 hasLocation W20258575812 @default.
- W2025857581 hasOpenAccess W2025857581 @default.
- W2025857581 hasPrimaryLocation W20258575811 @default.
- W2025857581 hasRelatedWork W1971567297 @default.
- W2025857581 hasRelatedWork W2025635333 @default.
- W2025857581 hasRelatedWork W2040963693 @default.
- W2025857581 hasRelatedWork W2078407092 @default.
- W2025857581 hasRelatedWork W2115143029 @default.
- W2025857581 hasRelatedWork W2419343612 @default.
- W2025857581 hasRelatedWork W2619595513 @default.
- W2025857581 hasRelatedWork W2965662303 @default.
- W2025857581 hasRelatedWork W4238927772 @default.
- W2025857581 hasRelatedWork W4247656164 @default.
- W2025857581 hasVolume "43" @default.
- W2025857581 isParatext "false" @default.
- W2025857581 isRetracted "false" @default.
- W2025857581 magId "2025857581" @default.
- W2025857581 workType "article" @default.